{"id":"dolutegravir-film-coated-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dolutegravir is an integrase strand transfer inhibitor (INSTI) that binds to HIV integrase and blocks the enzyme's ability to catalyze the integration of viral DNA into the human genome. By preventing this critical step in the HIV replication cycle, the drug stops viral propagation and reduces viral load in infected individuals. This mechanism allows for effective suppression of HIV replication with a high genetic barrier to resistance.","oneSentence":"Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:47.117Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve adults"},{"name":"HIV-1 infection in treatment-experienced adults"},{"name":"HIV-1 infection in adolescents and children (weight-based dosing)"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT05993767","phase":"PHASE2","title":"UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children","status":"COMPLETED","sponsor":"PENTA Foundation","startDate":"2024-12-11","conditions":"HIV Infection","enrollment":53},{"nctId":"NCT04337450","phase":"PHASE2, PHASE3","title":"DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old","status":"ACTIVE_NOT_RECRUITING","sponsor":"PENTA Foundation","startDate":"2022-04-22","conditions":"HIV Infections","enrollment":386},{"nctId":"NCT05630638","phase":"PHASE4","title":"Doravirine Dose Optimisation in Pregnancy","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2023-10-10","conditions":"HIV","enrollment":76},{"nctId":"NCT03016533","phase":"PHASE3","title":"Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT04880785","phase":"PHASE2","title":"Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2021-07-28","conditions":"HIV Infections","enrollment":121},{"nctId":"NCT01302847","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-04-20","conditions":"HIV Infections","enrollment":181},{"nctId":"NCT06450275","phase":"PHASE1","title":"Bioequivalence Study to Compare Dolutegravir 50mg Film-coated Tablets","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2024-01-03","conditions":"HIV Infections","enrollment":32},{"nctId":"NCT02831764","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-18","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":722},{"nctId":"NCT04021290","phase":"PHASE3","title":"Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-11-11","conditions":"HIV Infections","enrollment":493},{"nctId":"NCT02831673","phase":"PHASE3","title":"An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-07-21","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":719},{"nctId":"NCT03446573","phase":"PHASE3","title":"Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-01-18","conditions":"HIV Infections","enrollment":743},{"nctId":"NCT04302896","phase":"EARLY_PHASE1","title":"Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs","status":"COMPLETED","sponsor":"Rhonda Brand","startDate":"2020-08-31","conditions":"Medication Adherence, HIV","enrollment":30},{"nctId":"NCT03706898","phase":"PHASE1","title":"Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-10-01","conditions":"HIV-1-infection, Hepatic Impairment","enrollment":36},{"nctId":"NCT03945981","phase":"PHASE3","title":"Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-07-02","conditions":"HIV Infections","enrollment":131},{"nctId":"NCT02178592","phase":"PHASE3","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-01-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":113},{"nctId":"NCT03539224","phase":"PHASE2","title":"Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.","status":"UNKNOWN","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2017-11-02","conditions":"HIV-1-infection","enrollment":41},{"nctId":"NCT02741557","phase":"PHASE1","title":"Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-05-11","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":118},{"nctId":"NCT03078556","phase":"PHASE1","title":"Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-03-27","conditions":"Infection, Human Immunodeficiency Virus","enrollment":154},{"nctId":"NCT02500446","phase":"PHASE4","title":"Dolutegravir Impact on Residual Replication","status":"COMPLETED","sponsor":"University of Melbourne","startDate":"2015-09-28","conditions":"HIV","enrollment":40},{"nctId":"NCT02893488","phase":"PHASE1","title":"Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-09-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":20},{"nctId":"NCT02738931","phase":"PHASE1","title":"Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":30},{"nctId":"NCT02373930","phase":"PHASE1","title":"Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-02","conditions":"Infection, Human Immunodeficiency Virus","enrollment":63},{"nctId":"NCT02082808","phase":"PHASE1","title":"Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-03","conditions":"Infection, Human Immunodeficiency Virus","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Dolutegravir film-coated tablets","genericName":"Dolutegravir film-coated tablets","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dolutegravir inhibits HIV integrase, preventing the virus from integrating its genetic material into the host cell's DNA. Used for HIV-1 infection in treatment-naïve adults, HIV-1 infection in treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}